查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1990348

生物可分解支架市場：按產品類型、材料、應用和最終用戶分類的全球市場預測 – 2026-2032 年

Biodegradable Stents Market by Product Type, Material, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，可生物分解支架市場價值將達到 4.4859 億美元，到 2026 年將成長至 4.6924 億美元，複合年成長率為 5.19%，到 2032 年將達到 6.3932 億美元。

主要市場統計數據
基準年 2025 4.4859億美元
預計年份：2026年 4.6924億美元
預測年份：2032年 6.3932億美元
複合年成長率 (%) 5.19%

這是一本權威的生物可分解支架入門指南。內容涵蓋臨床進展、材料方面的重大進步、法規環境以及策略部署趨勢。

生物可分解支架透過提供臨時機械支撐，最大限度地減少異物長期滯留，正在為介入性心臟病學和血管內治療帶來模式轉移。這項技術的發展歷程已從早期臨床應用難度較高的聚合物支架，演變為現今注重材料科學、可控吸收動力學和遞送方式的多樣化平台方案。如今，臨床醫生、器械工程師和醫院採購團隊在評估這些產品時，不僅關注支架的短期性能，還關注中長期血管治療效果、影像學相容性以及對再次介入治療的影響。

材料科學、成像技術和混合商業化模式的進步如何推動下一波可生物分解支架的臨床應用和技術差異化？

生物可分解支架領域正經歷變革性的轉變，重塑臨床預期、生產重點和商業化策略。從第一代生物可吸收血管支架中汲取的早期經驗促使臨床實驗室設計、植入尺寸確定和影像學追蹤採取更嚴謹的方法，從而推動研發人員改善支架梁形態、徑向強度和吸收時間。這些技術改進，以及輔助成像技術（光學同調斷層掃描和高解析度血管內成像）的進步，使得對支架與組織整合情況和血管治療狀態進行詳細評估成為可能，這有助於監管申報和增強臨床醫生的信心。

評估 2025 年的累積關稅措施如何重塑可生物分解支架領域的採購經濟、製造地和臨床部署時間表。

2025年實施或擴大的累積關稅措施對可生物分解支架生態系相關相關人員的採購經濟、供應鏈建構和採購決策產生了實質影響。對某些原料和成品醫療設備徵收的關稅推高了依賴跨境供應關鍵原料（例如高純度鎂合金和特殊聚合物）的製造商的最終成本，同時也提高了醫院採購委員會的價格敏感度。為應對這項挑戰，製造商正在加快雙源採購策略的實施，實現生產基地的地域多角化，並明確長期供應商契約，以降低貿易政策進一步波動帶來的風險。

詳細的細分分析揭示了影響可生物分解支架技術採用的臨床定位、材料權衡和市場差異化因素。

細分市場分析揭示了清晰的臨床、技術和商業性趨勢，這些趨勢指導著產品、材料、應用、終端用戶和分銷等各個維度的策略優先排序。依產品類型分類，競爭產品線分為可生物分解聚合物塗層金屬支架和可生物吸收血管支架，後者進一步細分為球囊擴張式和自擴張式裝置。這些指南至關重要，因為輸送性能、徑向支撐力和展開精確度會影響臨床醫生的選擇和手術流程。依材料分類，平台主要集中在鎂合金或聚左旋乳酸(PLA) 基材上，而聚左旋乳酸的各種變體，例如複合 PLA 和 PLLA，會改變分解特性和成像特徵，從而影響追蹤通訊協定和患者選擇。

透過區域比較分析，揭示美洲、歐洲、中東和非洲以及亞太地區在監管差異、臨床引入模式和生產因素方面的細微差別。

生物可分解支架的區域表現和策略重點在美洲、歐洲、中東和非洲以及亞太地區存在顯著差異，這主要受法律規範、臨床實踐和生產能力的影響。美洲擁有先進的心臟導管介入網路和集中的高發心臟中心，是展示具有明顯手術優勢且與現有影像工作流程相容的器械的理想示範區。支付方的考慮和醫院的採購週期指南部署策略和循證方案的製定。在歐洲、中東和非洲，由於監管環境的碎片化和報銷計畫的多樣性，部署率各不相同。先進心臟中心的早期應用案例與需要更廣泛的衛生經濟學驗證才能說服支付方的市場並存。

公司層面的策略分析，重點在於可生物分解支架領域的創新路徑、夥伴關係模式和商業性競爭，進而推動競爭優勢。

生物分解支架領域的企業發展趨勢呈現出多元化的特點，既有成熟的循環系統製造商，也有專注於醫療技術創新的企業，還有整合了材料科學和監管專業知識的垂直整合供應商。主要企業持續投資於基於臨床醫生回饋的迭代產品開發、採用可靠影像學終點的受控臨床試驗以及旨在改善長期血管護理的上市後調查計畫。材料供應商與醫療設備製造商 (OEM) 之間的策略合作日益普遍，從而能夠快速改進合金成分、聚合物混合物和塗層化學，以最佳化吸收時間和機械性能。

為了加快企業採用可生物分解支架、確保供應鏈安全以及使臨床證據與商業策略保持一致，我們提出了可操作的跨部門建議。

產業領導者應協調臨床、生產和商業策略，以加速安全部署並降低營運風險。優先投資於嚴謹的臨床證據項目，利用高解析度成像和真實世界臨床註冊數據，在明確定義的患者群體中驗證支架的生物相容性、長期管腔行為和對比療效。這些數據有助於增強臨床醫生的信心，並支持差異化品牌建立。同時，透過多元化鎂合金和特殊聚合物的原料來源、探索本地組裝方案以及建立戰略庫存緩衝，降低供應鏈風險，以應對貿易政策波動和零件短缺。

為了支持我們的策略見解，我們採用了一種透明的多模態調查方法，結合了臨床證據、監管審查、專家訪談和供應鏈分析。

本研究採用多模態調查方法，整合了同行評審的臨床文獻、監管指導文件、醫療設備標籤檢視以及對臨床醫生、供應鏈專家和行業高管的訪談，以得出平衡且基於證據的結論。在整合臨床證據時，優先考慮隨機對照試驗和以影像學終點為指標的前瞻性觀察性研究，同時納入專家問捲和結構化訪談作為補充分析，以了解從業人員的經驗、應用障礙和培訓需求。監管審查考慮了區域核准流程和上市後監測要求，尤其關注與可吸收材料和支架相關終點相關的器材特定要求。

為了負責任地擴大可生物分解支架的使用，需要總結技術成熟度、臨床實施路徑和策略重點。

生物可分解支架正處於一個轉折點，材料的進步、實用混合設計的出現以及更嚴格的臨床評估，預計將生物可分解技術的未來潛力轉化為可靠的臨床應用。該領域已從前幾代產品的挑戰中吸取經驗，並開發出能夠更好地平衡急性期機械性能要求與可控分解、親和性以及更精密的植入系統的新技術。儘管不同臨床環境和地區的應用情況可能有所不同，但器械性能、臨床醫生培訓和監管規定的累積完善，為生物可分解支架更廣泛地應用於心臟和外周介入治療提供了切實可行的途徑。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 生物可分解支架市場：依產品類型分類

  • 可生物分解聚合物塗層金屬支架
  • 生物可吸收血管支架
    • 氣球膨脹類型
    • 自膨脹型

第9章：可生物分解支架市場：依材料分類

  • 鎂合金
  • 聚左旋乳酸（PLLA）
    • 複合PLA
    • PLLA

第10章：可生物分解支架市場：依應用領域分類

  • 冠狀動脈疾病
    • 急性心肌梗塞
    • 慢性完全閉塞
  • 周邊動脈疾病

第11章 生物可分解支架市場：依最終用戶分類

  • 門診手術中心
  • 醫院
    • 心臟中心
    • 循環系統

第12章 可生物分解支架市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 生物可分解支架市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 可生物分解支架市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國可生物分解支架市場

第16章：中國可生物分解支架市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Alvimedica
  • Amaranth Medical Inc.
  • Arterius Limited
  • BIoTronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Elixir Medical Corporation
  • Kyoto Medical Planning Co. Ltd.
  • Lepu Medical Technology Co. Ltd.
  • Medtronic PLC
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • OrbusNeich Medical Company Limited
  • REVA Medical LLC
  • S3V Vascular Technologies
  • Terumo Corporation
  • Xenogenics Corporation
Product Code: MRR-4D00F1312C7E

The Biodegradable Stents Market was valued at USD 448.59 million in 2025 and is projected to grow to USD 469.24 million in 2026, with a CAGR of 5.19%, reaching USD 639.32 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 448.59 million
Estimated Year [2026] USD 469.24 million
Forecast Year [2032] USD 639.32 million
CAGR (%) 5.19%

An authoritative introduction to biodegradable stents that frames clinical evolution, material breakthroughs, regulatory context, and strategic adoption dynamics

Biodegradable stents represent a paradigm shift in interventional cardiology and endovascular therapy, driven by the pursuit of transient mechanical support that minimizes long-term foreign-body presence. The technology arc has moved from early polymer-based scaffolds with high-profile clinical setbacks toward a diversified set of platform approaches that emphasize material science, controlled resorption kinetics, and deliverability. Clinicians, device engineers, and hospital procurement teams now evaluate these products not only on acute scaffold performance but on mid- and long-term vessel healing, imaging compatibility, and implications for repeat interventions.

Simultaneously, regulatory pathways and post-market surveillance frameworks have matured to incorporate device-specific endpoints such as late lumen loss, scaffold thrombosis, and vessel remodeling. This evolution has encouraged iterative improvements in magnesium alloy formulations and refinements to poly-L-lactic acid constructs, while also stimulating innovations around polymer coatings for metallic stents that aim to combine the immediate mechanical reliability of metal with a bioresorbable interface. As adoption considerations become more nuanced, strategic questions center on clinical positioning, comparative evidence generation, and supply chain resilience, all of which will determine how biodegradable platforms integrate into standard care algorithms.

How material science, imaging advances, and hybrid commercialization models are driving the next wave of clinical adoption and technology differentiation in biodegradable stents

The landscape for biodegradable stents has experienced transformative shifts that are reshaping clinical expectations, manufacturing priorities, and commercialization strategies. Early lessons from first-generation bioresorbable vascular scaffolds catalyzed a more disciplined approach to trial design, implant sizing, and imaging-driven follow-up, prompting developers to iterate on strut geometry, scaffold radial strength, and resorption timelines. These technical refinements are accompanied by advances in adjunctive imaging-optical coherence tomography and high-resolution intravascular imaging-that enable granular assessment of scaffold integration and vessel healing, thereby informing both regulatory submissions and clinician confidence.

Concurrently, materials innovation has broadened the available toolkit: magnesium alloy platforms emphasize more rapid, controlled resorption with favorable mechanical profiles, while poly-L-lactic acid-based solutions focus on prolonged structural support with tunable degradation. The lines between permanent metal stents and bioresorbable concepts are blurring through hybrid approaches such as biodegradable polymer coatings on metallic scaffolds, which seek to balance long-term patency with reduced chronic inflammation. Market participants are also recalibrating commercial models, with suppliers prioritizing robust clinical evidence, tailored training programs for operators, and service-oriented post-market follow-up to accelerate adoption within centers of excellence and cardiology networks.

Assessment of how 2025 cumulative tariff actions have reshaped procurement economics, manufacturing footprints, and clinical adoption timelines in the biodegradable stent sector

Cumulative tariff measures enacted or expanded in 2025 exert a tangible influence on procurement economics, supply-chain structuring, and sourcing decisions for stakeholders in the biodegradable stent ecosystem. Tariffs on specific inputs and finished medical devices raise landed costs for manufacturers that rely on cross-border supply of critical raw materials such as high-purity magnesium alloy feedstock and specialty polymers, while also increasing the price sensitivity of hospital purchasing committees. In response, manufacturers have accelerated dual-sourcing strategies, regionalized production footprints, and clarified long-term supplier agreements to mitigate exposure to further trade policy volatility.

The tariff environment has also prompted a chain reaction that affects clinical adoption timing: health systems under cost pressure may delay elective procedures or prioritize devices with clearer near-term budgetary benefits, which in turn influences the cadence of evidence generation and real-world data collection. Some firms have adopted localized assembly and final testing to reduce tariff burdens on finished goods, thereby shifting capital investment and talent requirements toward regions with favorable trade treatments. Looking ahead, the cumulative effect of tariffs is better characterized as a driver of operational adaptation-reshaping pricing strategies, inventory policies, and partnership models-rather than a deterministic barrier to technological advancement.

In-depth segmentation insights that illuminate clinical positioning, material trade-offs, and go-to-market differentiators shaping adoption of biodegradable stent technologies

Segmentation analysis reveals distinct clinical, technical, and commercial dynamics across product, material, application, end-user, and distribution dimensions that guide strategic prioritization. Based on Product Type, the competitive set spans Biodegradable Polymer Coated Metallic Stents and Bioresorbable Vascular Scaffolds, with the latter further differentiated into Balloon Expandable and Self Expanding devices; these distinctions matter because deliverability, radial strength, and deployment precision influence operator preference and procedural workflows. Based on Material, platforms gravitate toward Magnesium Alloy or Poly-L-Lactic Acid substrates, where Poly-L-Lactic Acid variations such as Composite PLA and PLLA alter degradation profiles and imaging signatures, affecting follow-up protocols and patient selection.

Based on Application, clinical targeting bifurcates between Coronary Artery Disease and Peripheral Artery Disease, with Coronary Artery Disease use later stratified into Acute Myocardial Infarction and Chronic Total Occlusion contexts that present different lesion morphologies and risk tolerances. Based on End User, adoption pathways differ between Ambulatory Surgery Centers and Hospitals, and within hospitals the dynamics vary between Cardiac Centers and Cardiology Departments because high-volume, specialized cardiac centers often accelerate procedural innovations. Finally, based on Distribution Channel, commercial approaches split across Direct Sales and Distributors, and direct-sales models that deploy In House Sales Teams or Original Equipment Manufacturer partnerships change customer engagement intensity and post-sale service expectations. Understanding these segmentation layers clarifies where clinical evidence, training, and supply continuity will most effectively translate into adoption and commercial success.

Comparative regional intelligence that decodes regulatory nuances, clinical adoption patterns, and manufacturing influences across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional performance and strategic priorities for biodegradable stents differ markedly across the Americas, Europe, Middle East & Africa, and Asia-Pacific, driven by regulatory frameworks, clinical practices, and manufacturing capacity. In the Americas, advanced interventional cardiology networks and a concentrated set of high-volume cardiac centers make the region a proving ground for devices that demonstrate clear procedural advantages and compatibility with existing imaging workflows; payer considerations and hospital procurement cycles inform rollout strategies and evidence generation plans. In Europe, Middle East & Africa, fragmented regulatory landscapes and varied reimbursement policies create a mosaic of adoption speeds, where early adopters in advanced cardiac centers coexist with markets that require more extensive health-economic demonstration to convince payers.

The Asia-Pacific region combines rapidly expanding procedural volumes with strong manufacturing ecosystems and an increasing appetite for locally produced solutions. Local clinical investigators and regional regulators are playing a more visible role in shaping device design and post-market evidence requirements. Across all regions, differences in operator training pathways, hospital procurement practices, and supply chain resiliency underscore the need for nuanced regional commercialization roadmaps that align clinical data campaigns with local regulatory expectations and distribution capabilities. Harmonizing global clinical evidence strategies with region-specific value propositions will be decisive for organizations seeking multi-regional scale.

Strategic company-level analysis that highlights innovation pathways, partnership models, and commercial competencies driving competitive advantage in biodegradable stents

Company-level dynamics in the biodegradable stent domain are characterized by a mix of incumbent cardiovascular device manufacturers, specialized medtech innovators, and vertically integrated suppliers that combine materials science with regulatory expertise. Leading organizations consistently invest in iterative product development informed by operator feedback, controlled clinical studies with robust imaging endpoints, and post-market surveillance programs that address long-term vessel healing. Strategic partnerships between material suppliers and device OEMs are increasingly common, enabling faster optimization of alloy compositions, polymer blends, and coating chemistries that refine resorption timing and mechanical performance.

Smaller, more agile entrants focus on niche indications or platform enhancements-such as lower-profile delivery systems, hybrid scaffolds, or adjunctive imaging software-targeting centers of excellence where adoption velocity is highest. Across the competitive landscape, successful companies exhibit disciplined regulatory strategies, clear training and proctoring pathways for clinicians, and pragmatic pricing models that consider hospital capital constraints and procedural reimbursement realities. As supply-chain pressures and tariff-related cost dynamics continue to influence unit economics, firms with diversified manufacturing footprints and flexible distribution agreements will maintain tactical advantages in sustaining commercial momentum.

Actionable, cross-functional recommendations for companies to accelerate adoption, secure supply chains, and align clinical evidence with commercial strategies in biodegradable stents

Industry leaders should align clinical, manufacturing, and commercial strategies to accelerate safe adoption while mitigating operational risk. Prioritize investment in rigorous clinical evidence programs that leverage high-resolution imaging and real-world registries to demonstrate scaffold integration, late lumen behavior, and comparative outcomes in clearly defined patient cohorts; such data builds clinician trust and supports differentiated labeling. Concurrently, de-risk supply chains by diversifying raw-material sources for magnesium alloys and specialty polymers, exploring localized assembly options, and instituting strategic inventory buffers to guard against trade-policy disruptions or component shortages.

Commercially, tailor engagement models to end-user profiles: provide hands-on training and proctoring for cardiac centers that drive early adoption while offering simplified procurement pathways and technical support for ambulatory surgery centers. Emphasize hybrid product families-biodegradable polymer coatings on metallic platforms or hybrid scaffolds-that address the clinical demand for predictable acute performance with reduced long-term device footprint. Finally, adopt value-based pricing discussions with payers by correlating device attributes with procedural efficiency, reduced long-term complications, and potential downstream cost offsets, thereby aligning reimbursement conversations with clinical and economic evidence.

A transparent, multi-modal research methodology combining clinical evidence synthesis, regulatory review, expert interviews, and supply-chain analysis to underpin strategic insights

The research employed a multi-modal methodology that integrates peer-reviewed clinical literature, regulatory guidance documents, device labeling, and interviews with clinicians, supply-chain specialists, and industry executives to ensure balanced, evidence-driven conclusions. Clinical evidence synthesis prioritized randomized and prospective observational studies with imaging-based endpoints, while complementary analyses incorporated expert surveys and structured interviews to capture operator experience, adoption barriers, and training needs. Regulatory review considered regional pathways and post-market surveillance expectations, with attention to device-specific requirements for resorbable materials and scaffold-related endpoints.

Supply-chain and tariff analyses combined customs and trade policy reviews with interviews of procurement managers and component suppliers to map exposure to input-cost volatility and logistical constraints. Commercial modeling focused on segmentation-driven adoption scenarios without projecting aggregate market sizes, using case-study approaches to illustrate how product design, distribution strategy, and regional regulatory alignment influence commercial outcomes. Throughout, methodological triangulation-cross-verifying insights from clinical, regulatory, and commercial sources-was used to increase the robustness of findings and to highlight areas where targeted primary research would most effectively close evidence gaps.

A concise conclusion that synthesizes technology readiness, clinical adoption pathways, and strategic priorities for responsible expansion of biodegradable stent use

Biodegradable stents now stand at an inflection point where material advances, pragmatic hybrid designs, and more rigorous clinical evaluation can translate the promise of resorbable technology into durable clinical use. The field has learned from early generational challenges and has responded with technologies that better balance acute mechanical needs with controlled degradation, enhanced imaging compatibility, and refined deployment systems. Adoption will be uneven across clinical contexts and geographies, but the cumulative progress in device performance, clinician training, and regulatory clarity provides a realistic pathway for broader integration into interventional cardiology and peripheral interventions.

Successful stakeholders will be those who combine strong clinical evidence strategies with resilient manufacturing and distribution approaches, mindful of trade-policy and reimbursement dynamics. By focusing on clear clinical differentiation, localized commercial execution, and systematic post-market learnings, the industry can responsibly expand device availability while preserving patient safety and procedural effectiveness. The trajectory for biodegradable stents is not a simple replacement of permanent implants but a more nuanced expansion of therapeutic options that can be tailored to patient risk profiles and lesion characteristics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biodegradable Stents Market, by Product Type

  • 8.1. Biodegradable Polymer Coated Metallic Stents
  • 8.2. Bioresorbable Vascular Scaffolds
    • 8.2.1. Balloon Expandable
    • 8.2.2. Self Expanding

9. Biodegradable Stents Market, by Material

  • 9.1. Magnesium Alloy
  • 9.2. Poly-L-Lactic Acid
    • 9.2.1. Composite Pla
    • 9.2.2. Plla

10. Biodegradable Stents Market, by Application

  • 10.1. Coronary Artery Disease
    • 10.1.1. Acute Myocardial Infarction
    • 10.1.2. Chronic Total Occlusion
  • 10.2. Peripheral Artery Disease

11. Biodegradable Stents Market, by End User

  • 11.1. Ambulatory Surgery Centers
  • 11.2. Hospitals
    • 11.2.1. Cardiac Centers
    • 11.2.2. Cardiology Departments

12. Biodegradable Stents Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Biodegradable Stents Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Biodegradable Stents Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Biodegradable Stents Market

16. China Biodegradable Stents Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Alvimedica
  • 17.7. Amaranth Medical Inc.
  • 17.8. Arterius Limited
  • 17.9. Biotronik SE & Co. KG
  • 17.10. Boston Scientific Corporation
  • 17.11. Cardionovum GmbH
  • 17.12. Elixir Medical Corporation
  • 17.13. Kyoto Medical Planning Co. Ltd.
  • 17.14. Lepu Medical Technology Co. Ltd.
  • 17.15. Medtronic PLC
  • 17.16. Meril Life Sciences Pvt. Ltd.
  • 17.17. MicroPort Scientific Corporation
  • 17.18. OrbusNeich Medical Company Limited
  • 17.19. REVA Medical LLC
  • 17.20. S3V Vascular Technologies
  • 17.21. Terumo Corporation
  • 17.22. Xenogenics Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIODEGRADABLE STENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIODEGRADABLE STENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BIODEGRADABLE STENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIODEGRADABLE POLYMER COATED METALLIC STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIODEGRADABLE POLYMER COATED METALLIC STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIODEGRADABLE POLYMER COATED METALLIC STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY BALLOON EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY SELF EXPANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY MAGNESIUM ALLOY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY MAGNESIUM ALLOY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY MAGNESIUM ALLOY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY COMPOSITE PLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY COMPOSITE PLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY COMPOSITE PLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PLLA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PLLA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PLLA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY ACUTE MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CHRONIC TOTAL OCCLUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CARDIOLOGY DEPARTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CARDIOLOGY DEPARTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY CARDIOLOGY DEPARTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 141. GCC BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GCC BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 144. GCC BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 145. GCC BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 168. G7 BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. G7 BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 172. G7 BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 177. NATO BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 181. NATO BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 182. NATO BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. NATO BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 184. NATO BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. NATO BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BIODEGRADABLE STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BIODEGRADABLE STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY BIORESORBABLE VASCULAR SCAFFOLDS, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY POLY-L-LACTIC ACID, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY CORONARY ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA BIODEGRADABLE STENTS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)